Orthopedic Devices Market Size, Share, Growth and Forecast, 2025-2035

Joint replacement and spine care anchor implant demand

The global orthopedic devices market was valued at USD 52.01 billion in 2025 and is projected to increase from USD 54.15 billion in 2026 to USD 77.86 billion by 2035, registering a CAGR of 4.12% during 2026–2035. Demand comes from aging populations, a rising burden of osteoarthritis and back pain, sports and trauma injuries and the spread of joint replacement in emerging economies. North America held the largest regional share, 42.0% in 2025, because U.S. hospitals and surgery centers perform high volumes of knee, hip and spine procedures with premium implants. Asia Pacific is the fastest-growing region at 5.26% a year, as China, India and Southeast Asia expand surgical capacity. The payment picture changed in January 2026, when a mandatory U.S. hospital payment model began holding hospitals accountable for full episodes of joint replacement, hip fracture and spinal fusion care. As a result, hospitals now weigh implant cost and recovery outcomes together.

Which musculoskeletal products does this analysis cover?

The analysis counts joint replacement implants, fixation plates, screws and nails, spinal implants and instruments, arthroscopy instruments, orthobiologics, bone graft substitutes, external prosthetics and braces and supports. Values are based on manufacturer selling prices, including instruments and enabling technology sold with implants.

Physical therapy services, surgeon fees and general hospital equipment sit outside the scope of this analysis. The value chain runs from material, coating and machining suppliers through implant makers and distributors to hospitals, ambulatory surgery centers, specialist clinics and home care providers.

Joint replacement leads as orthobiologics grow fastest

Why do replacement implants lead product spending?

Based on product, the market is categorized into replacement devices, spinal implants and surgical devices, fixation devices, braces and support products, arthroscopy instruments, orthobiologics, bone graft substitutes and prosthetics. Orthopedic Replacement Devices led with a 30.0% share of 2025 value, because hip and knee procedures use high-value implant systems. Orthobiologics grow fastest at 4.91% a year, as surgeons use biologic materials to support fusion and healing, often alongside bone graft substitutes.

Why do foot and ankle implants grow fastest?

Based on site, the market is categorized into knee and thigh, shoulder, hip, hand and wrist, foot and ankle, spine, arm and elbow, craniomaxillofacial and other sites. Knee and Thigh Implants led with a 27.0% share of 2025 value, because knee replacement is the most common joint operation in many countries. Foot and Ankle Implants grow fastest at 4.95% a year, as specialist companies bring dedicated implants and instruments to this area.

Why are ambulatory care centers gaining surgical volume?

Based on end user, the market is categorized into hospitals, ambulatory care centers, orthopedic centers, specialized clinics, home care settings and others. Hospitals led with a 55.0% share of 2025 value, because trauma, revision and complex spine cases need inpatient care. Ambulatory Care Centers grow fastest at 5.18% a year, as payers and surgeons move routine joint replacement to same-day settings.

Aging, arthritis and back pain lift surgical volumes

How does the rising burden of osteoarthritis sustain demand?

The rising burden of osteoarthritis sustains demand, because damaged knees and hips often end in joint replacement. The World Health Organization says about 528 million people were living with osteoarthritis in 2019, an increase of 113% since 1990. About 70% of people with the condition are older than 55, and about 60% are women. WHO also notes that joint replacement surgery is most commonly performed at the hip and knee. As a result, replacement devices held 30.0% of 2025 value, the largest product share. In turn, earlier diagnosis and better access to surgery keep adding patients in middle-income countries, where joint replacement is still far less common than in high-income markets.

Why does population aging raise surgical volumes?

Population aging raises surgical volumes, because bone and joint disease becomes more common with each decade of life. WHO projects that by 2030, 1 in 6 people worldwide will be aged 60 or over, and the number aged 80 or older will triple between 2020 and 2050 to 426 million. Older patients also face more fragility fractures, which need plates, nails and screws. In the United States, national survey data for 2019 show that 57.8% of women aged 75 or older had arthritis, compared with 6.6% of women aged 18 to 44. As a result, demand rises fastest in the oldest age groups, where joint replacement and fracture repair are most common.

Download Free Sample

How does back pain drive spinal implant demand?

Back pain drives spinal implant demand, because degenerative spine disease is a leading cause of disability. WHO estimates that low back pain affected 619 million people in 2020, and cases could reach 843 million by 2050. Most patients receive conservative care, but those with instability, deformity or nerve compression may need fusion surgery with spinal implants. Spine accounts for a large share of site value, behind knee and hip work. In turn, new navigation and robotic tools are making complex spine surgery more predictable, which supports wider adoption. In March 2025, Stryker said it had completed its first Mako Spine cases, which shows how robotic guidance is moving from joints into spine work.

Why do robotic systems raise spending per procedure?

Robotic systems raise spending per procedure, because hospitals buy capital equipment and linked implant systems together. In March 2025, Stryker said more than 1.5 million Mako procedures had been performed in 45 countries, and it made its fourth-generation Mako 4 system commercially available. Mako 4 covers total hip, total knee, partial knee and spine applications, and Stryker completed first Mako Spine cases in October 2024. In October 2025, Zimmer Biomet completed its acquisition of Monogram Technologies, a developer of autonomous robotic knee surgery. As a result, robots tie hospitals to a single implant supplier for many years, which raises the value of each installed system.

Robotics, outpatient surgery and deals reshape the field

How are payment models shifting joint surgery decisions?

Payment models are shifting joint surgery decisions, because hospitals now carry more financial risk for whole episodes of care. The Transforming Episode Accountability Model began on Jan. 1, 2026, and runs for five years as a mandatory, episode-based program. It covers lower extremity joint replacement, surgical hip and femur fracture treatment and spinal fusion, along with 2 other surgical episodes. Hospitals in the model are rewarded for lower total cost and better outcomes after surgery. As a result, buyers compare implant prices, readmission rates and recovery times more closely, and same-day surgery gains ground in many hospital systems. Suppliers that share outcome data with hospitals gain an edge in these contract talks.

Why are focused acquisitions rising among large suppliers?

Focused acquisitions are rising among large suppliers, because companies want leadership in faster-growing joint and extremity niches. In April 2025, Zimmer Biomet completed its acquisition of Paragon 28, a company focused exclusively on foot and ankle care. In January 2024, Enovis closed its purchase of LimaCorporate, adding shoulder implants and revision offerings in extremities. In October 2025, Johnson & Johnson announced plans to separate DePuy Synthes into a standalone company serving upwards of 7 million patients a year. In turn, foot and ankle implants grow at 4.95% a year, the fastest site and other large suppliers are reviewing their own portfolios for similar moves.

Download Free Sample

Can outpatient joint surgery open new demand?

Suppliers have a clear opening in outpatient joint surgery, because surgery centers need compact instrument sets, efficient implant systems and fast recovery protocols. Hospitals still held 55.0% of 2025 value, but ambulatory care centers grow fastest at 5.18% a year. The TEAM model, which began on Jan. 1, 2026, adds pressure on hospitals to shorten stays for patients who need osteoarthritis treatment through knee and hip replacement. Stryker also kept Mako Shoulder in limited market release through 2025, which brings robotic planning to more shoulder cases. As a result, suppliers that support same-day discharge can win new accounts, especially among surgeon-owned centers that buy directly.

Where can sports medicine and arthroscopy add demand?

Sports medicine gives suppliers room to add demand, because active adults want faster return to work and sport after injury. Arthroscopy allows surgeons to repair ligaments, tendons and cartilage through small incisions with shorter recovery. Arthrex, Inc., Smith+Nephew and CONMED Corporation compete with instruments, anchors and visualization systems in this area. In January 2024, Enovis also expanded in extremities through its LimaCorporate purchase, which included shoulder products for active patients. In 2019, 22.3% of U.S. men aged 45 to 64 reported arthritis, according to CDC survey data, and many of these adults still want active lifestyles. In turn, arthroscopy instruments and orthobiologics, which grow fastest among products at 4.91% a year, can outpace the overall market.

Pricing, payment reform and recalls pressure suppliers

Why does pricing pressure squeeze implant margins?

Pricing pressure squeezes implant margins, because hospitals, group purchasing organizations and public tenders push for lower costs on standard implants. Volume-based procurement in China has cut prices sharply for joint and spine products. Bundled payments in the United States also cap the money available for each procedure. As a result, suppliers rely on enabling technology, service and broader portfolios to protect their pricing.

How do episode payment rules raise risk for hospitals?

Episode payment rules raise risk for hospitals, because they become responsible for costs well after the operation ends. Readmissions, complications and long rehabilitation stays now affect hospital payments directly. Smaller hospitals may lack the data and care coordination tools needed to manage this risk. In turn, some delay purchases of premium implants or capital equipment until savings are proven in their own settings.

Why do recalls and regulatory demands slow product entry?

Recalls and regulatory demands slow product entry, because implants stay in the body for many years and failures affect patients deeply. Regulators in the United States and Europe require stronger clinical evidence and post-market tracking than in the past. The European Union medical device regulation has raised documentation work for older products. As a result, some smaller suppliers withdraw products instead of paying for new studies.

How do surgeon and staff shortages limit procedure growth?

Surgeon and staff shortages limit procedure growth, because joint and spine operations need trained surgeons, anesthesia teams and nurses. Many low and middle-income countries have too few orthopedic surgeons for their aging populations. Waiting lists for hip and knee surgery remain long in several public health systems. In turn, suppliers invest in training programs, robotic guidance and simplified instruments to raise surgical capacity.

North America leads as Asia Pacific gains pace

Why do U.S. procedure volumes keep North America in the lead?

North America held a 42.0% share of 2025 value and grows at 3.76% a year through 2035. The United States drives this position, because hospitals and surgery centers perform large volumes of joint, spine and trauma procedures with premium implants. Robotic systems from Stryker, Zimmer Biomet and others are widely installed, and Stryker launched Mako 4 there in 2025. The TEAM payment model, which began in January 2026, pushes buyers to weigh outcomes and cost together.

How do European tenders shape implant purchases?

Europe held a 27.0% share of 2025 value and grows at 3.56% a year, the slowest pace of the five regions. Germany, France, Italy and the United Kingdom account for much of the spending, and suppliers such as B. Braun SE and Institut Straumann AG are based in the region. However, public tenders, joint registries and long waiting lists keep value growth below the global average.

Download Free Sample

Why do China and India drive Asia Pacific growth?

Asia Pacific held a 21.0% share of 2025 value and is the fastest-growing region at 5.26% a year. China and India are expanding hospital capacity and joint replacement access, while Japan and South Korea have large aging populations. Local makers such as OSSTEM IMPLANT CO., LTD. and Narang Medical Limited compete on price with global brands. This mix of volume growth and local supply keeps average prices lower.

Why are private hospitals lifting Latin American demand?

Latin America held a 6.0% share of 2025 value and grows at 4.56% a year through 2035. Brazil and Mexico lead regional spending, because private hospitals and insurers are expanding joint and trauma surgery. Road injuries also keep fixation demand steady across the region.

Why does the Middle East and Africa remain a small market?

The Middle East and Africa held a 4.0% share of 2025 value and grows at 4.66% a year through 2035. Gulf states fund modern orthopedic hospitals, while much of Africa has few specialist surgeons. This gap limits implant use outside major cities and private centers.

Download Free Sample

Acquisitions, launches and spinoffs since 2024

Robotic guidance, 3D printing and biologics advance

• Robotic surgical guidance plans and positions implants with high accuracy, which helps surgeons reduce variation in knee, hip and spine cases.
• 3D-printed porous implants allow bone to grow into the implant surface, which supports fixation in spine and revision joint surgery.
• Orthobiologic materials support bone healing and spinal fusion, which reduces the need for bone taken from the patient.
• Patient-specific planning software builds surgical plans from imaging scans, which shortens operating time and improves implant fit.
• Connected recovery tools track patient mobility after surgery, which helps hospitals manage outcomes under episode payment models.

Musculoskeletal suppliers compete on robots and breadth

Competition is led by a group of large musculoskeletal companies with broad implant portfolios and robotic platforms. Stryker, Zimmer Biomet, Smith+Nephew and Medtronic compete in joint replacement, trauma, spine and enabling technology. Globus Medical, which combined with NuVasive, Inc., focuses on spine implants and navigation. Enovis Corporation competes in joint reconstruction, extremities and bracing, and the German group B. Braun SE supplies joint implants, while Arthrex, Inc. and CONMED Corporation lead in sports medicine and arthroscopy. Integra LifeSciences Corporation adds biologic, nerve repair and extremity products to the field. Institut Straumann AG and OSSTEM IMPLANT CO., LTD. supply dental and maxillofacial implants, and Narang Medical Limited serves price-sensitive markets. As a result, buyers favor suppliers that combine implants, robots and service.

Companies profiled and their roles in this market

Outpatient joint surgery sets the growth pace

Credence Research's view is that outpatient joint surgery will set the pace of growth through 2035, because payers and surgeons want shorter stays and predictable costs. The overall market grows at 4.12% a year, supported by aging, arthritis and back pain. Robotic systems and orthobiologics grow faster than standard trauma products as hospitals invest in outcomes. Companies that combine implant breadth, enabling technology and same-day surgery support will win the most hospital and surgery center contracts.

How Credence Research sized musculoskeletal implants

The report uses 2025 as the base year and 2026 to 2035 as the forecast period. Market values come from the Credence Research model, which builds spending by product, site, end user and region. Regional and segment splits are Credence Research estimates informed by World Health Organization and U.S. government statistics, SEC filings and company press releases. No primary interviews or surveys were used in preparing this edition of the report.

Musculoskeletal implant outlook to 2035

By 2035, the orthopedic devices market is projected to reach USD 77.86 billion, with growth led by joint replacement, spine care and orthobiologics. Replacement devices will remain the largest product area, while foot, ankle and shoulder work expands fastest by site. North America keeps the highest spending per procedure, and Asia Pacific adds the most new patients. Routine joint surgery will move further into ambulatory care centers under episode payment models. As a result, advantage will depend on robots, implant breadth and service.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.